mRNA specialist Moderna (MRNA) is among the leading players in the race to be first to market with a COVID-19 vaccine and the market has been kind in return. Overall,
mRNA specialist Moderna (MRNA) is among the leading players in the race to be first to market with a COVID-19 vaccine and the market has been kind in return. Overall,
Moderna (MRNA) has taken the rare step of publishing the clinical protocols for its late-stage Covid-19 vaccine trials. The company also announced that it is planning to produce roughly 20M doses of
Moderna stock (MRNA) is up 2.7% in Thursday’s pre-market trading after the company inked a deal with Vertex Pharmaceuticals for the treatment of cystic fibrosis (CF) using gene editing. Moderna
The world needs a vaccine against COVID-19, and with some 200 vaccine candidates in various stages of development, and more than 30 of these vaccines already in Phase 3 clinical
Leading the charge towards development of a COVID-19 vaccine proved very profitable for unprofitable biotech Moderna (MRNA) this year. Despite a 10-year history of never earning money, Moderna stock soared